Bayer joins the COVID-19 vaccine push, backing CureVac shot

Shortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to roll the shot out at scale if it works as hoped.

3rd RNA-Targeted Drug Discovery Summit

Expanding RNA Druggability with Small Molecules

Moderna’s $37B market cap is too high, despite COVID-19 vacc...

JP Morgan has downgraded its valuation of Moderna, saying its $37 billion market cap is way too high even if its COVID-19 vaccine mRNA-1273 succeeds in clinical trials.

Can we target coronavirus RNA with siRNA drugs?

NEW: RNAi-Based Therapeutics Summit

Takeda signs $882m rare disease alliance with Oxford biotech...

Allergan bolsters aesthetics pipeline with Exicure hair loss...